{"id":"cam2029","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hyperhidrosis"}]},"_chembl":{"chemblId":"CHEMBL3545066","moleculeType":"Protein","molecularWeight":"1092.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAM2029 is a subcutaneous depot injection of buprenorphine that delivers the drug over an extended period, reducing the need for frequent dosing. Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid-dependent patients while carrying lower overdose risk than full agonists. The extended-release formulation aims to improve treatment adherence and reduce illicit opioid use.","oneSentence":"CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:59.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT04125836","phase":"PHASE3","title":"A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-10-10","conditions":"Acromegaly","enrollment":135},{"nctId":"NCT05281328","phase":"PHASE2, PHASE3","title":"A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2022-06-28","conditions":"Polycystic Liver Disease","enrollment":71},{"nctId":"NCT05050942","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2021-10-22","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":332},{"nctId":"NCT04076462","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-08-19","conditions":"Acromegaly","enrollment":72},{"nctId":"NCT02299089","phase":"PHASE2","title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2015-01","conditions":"Acromegaly, Neuroendocrine Tumors","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["octreotide subcutaneous depot"],"phase":"phase_3","status":"active","brandName":"CAM2029","genericName":"CAM2029","companyName":"Camurus AB","companyId":"camurus-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment. Used for Opioid use disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}